Description:
A phase 1b/2, open-label, multinational, interventional trial to evaluate the safety,
tolerability, PK, pharmacodynamics/biomarkers, immunogenicity, and preliminary efficacy of
epcoritamab in combination with other standard of care (SOC) agents in subjects with B-NHL.
Title
- Brief Title: Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma
- Official Title: A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma
Clinical Trial IDs
- ORG STUDY ID:
GCT3013-02
- NCT ID:
NCT04663347
Conditions
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
Interventions
Drug | Synonyms | Arms |
---|
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone | R-CHOP | Arm 1 - Epcoritamab + R-CHOP |
rituximab and lenalidomide | R2 | Arm 2 - Epcoritamab + R- Lenalidomide |
rituximab and bendamustine | BR | Arm 3 - Epcoritamab + BR |
rituximab, cisplatin, cytarabine, and dexamethasone | R-DHAX/C | Arm 4 - Epcoritamab + R-DHAX/C |
gemcitabine and oxaliplatin | GemOx | Arm 5 - Epcoritamab + GemOx |
Epcoritamab | GEN3013; DuoBody®-CD3xCD20 | Arm 1 - Epcoritamab + R-CHOP |
Purpose
A phase 1b/2, open-label, multinational, interventional trial to evaluate the safety,
tolerability, PK, pharmacodynamics/biomarkers, immunogenicity, and preliminary efficacy of
epcoritamab in combination with other standard of care (SOC) agents in subjects with B-NHL.
Detailed Description
The following regimens will be investigated:
- Arm 1: epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine, and
prednisone (R-CHOP) in subjects with previously untreated diffuse large B-cell lymphoma
(DLBCL)
- Arm 2: epcoritamab + rituximab and lenalidomide (R2) in subjects with
relapsed/refractory (R/R) follicular lymphoma (FL)
- Arm 3: epcoritamab + rituximab and bendamustine (BR) in subjects with previously
untreated FL
- Arm 4: epcoritamab + rituximab, cisplatin, cytarabine, and dexamethasone (R-DHAX/C) in
subjects with R/R DLBCL eligible for autologous stem cell transplant (ASCT)
- Arm 5: epcoritamab + gemcitabine and oxaliplatin (GemOx) in subjects with R/R DLBCL
ineligible for ASCT due to age, performance status (PS), or comorbidity
For each arm, there are 2 parts: Part 1 (dose escalation) and Part 2 (expansion). Within each
arm, subjects can only participate in one part.
Trial Arms
Name | Type | Description | Interventions |
---|
Arm 1 - Epcoritamab + R-CHOP | Experimental | Epcoritamab + R-CHOP in subjects with previously untreated DLBCL | - rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
- Epcoritamab
|
Arm 2 - Epcoritamab + R- Lenalidomide | Experimental | Epcoritamab + R- Lenalidomide in subjects with R/R FL | - rituximab and lenalidomide
- Epcoritamab
|
Arm 3 - Epcoritamab + BR | Experimental | Epcoritamab + BR in subjects with previously untreated FL | - rituximab and bendamustine
- Epcoritamab
|
Arm 4 - Epcoritamab + R-DHAX/C | Experimental | Epcoritamab + R-DHAX/C in subjects with R/R DLBCL Eligible ASCT | - rituximab, cisplatin, cytarabine, and dexamethasone
- Epcoritamab
|
Arm 5 - Epcoritamab + GemOx | Experimental | Epcoritamab + GemOx in subjects with R/R DLBCL Ineligible ASCT | - gemcitabine and oxaliplatin
- Epcoritamab
|
Eligibility Criteria
Inclusion Criteria
1. Subject must sign an ICF
2. At least 18 years of age
3. Measurable disease defined as ≥1 measurable nodal lesion (long axis >1.5 cm and short
axis >1.0 cm) or ≥1 measurable extra-nodal lesion (long axis >1.0 cm) on CT or MRI
4. ECOG PS score of 0, 1 or 2
5. Acceptable organ function at screening
6. CD20-positive NHL at most recent representative tumor biopsy
7. If of childbearing potential subject must practicing a highly effective method of
birth control
8. A man who is sexually active with a woman of childbearing potential must agree to use
a barrier method of birth control
9. Arm 1: Newly Diagnosed Documented DLBCL
- DLBCL, NOS
- "double-hit" or "triple-hit" DLBCL
- FL Grade 3B
Arm 2: R/R FL
Arm 3: Newly diagnosed, previously untreated FL grade 1-3A
Arm 4: Documented DLBCL and eligible for HDT-ASCT
- DLBCL, NOS
- "double-hit" or "triple-hit" DLBCL
- FL Grade 3B
Arm 5: Relapsed Documented DLBCL and ineligible for HDT-ASCT
- DLBCL, NOS
- "double-hit" or "triple-hit" DLBCL
- FL Grade 3B
Exclusion Criteria
1. Chemotherapy, radiation therapy, or major surgery within 4 weeks prior to the first
dose of epcoritamab
2. Any prior treatment with a bispecific antibody targeting CD3 and CD20.
3. Treatment with CAR-T therapy within 30 days prior to first dose of epcoritamab
4. Clinically significant cardiovascular disease
5. Evidence of significant, uncontrolled concomitant diseases that could affect
compliance with the protocol or interpretation of results
6. CNS lymphoma or known CNS involvement by lymphoma at screening as confirmed by MRI/CT
scan of the brain and, if clinically indicated, by lumbar puncture
7. Active positive tests for hepatitis B virus or hepatitis C virus indicating acute or
chronic infection
8. Known history of seropositivity of human immunodeficiency virus (HIV)
9. Positive test results for HTLV-1
10. Suspected active or latent tuberculosis
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Dose Escalation Phase - Number of dose-limiting toxicities (DLTs) |
Time Frame: | DLTs are evaluated during the first cycle (28 days) in each cohort |
Safety Issue: | |
Description: | To evaluate the safety of epcoritamab in combination with other agents |
Secondary Outcome Measures
Measure: | Pharmacokinetics concentration of epcoritamab |
Time Frame: | From start of treatment throughout all treatment cycles (each cycle is 28 days) until LPLV, approximately 3 years |
Safety Issue: | |
Description: | To evaluate PK parameter - Clearance |
Measure: | Pharmacokinetics concentration of epcoritamab |
Time Frame: | From start of treatment throughout all treatment cycles (each cycle is 28 days) until LPLV, approximately 3 years |
Safety Issue: | |
Description: | To evaluate PK parameter - Volume of distribution |
Measure: | Pharmacokinetics concentration of epcoritamab |
Time Frame: | From start of treatment throughout all treatment cycles (each cycle is 28 days) until LPLV, approximately 3 years |
Safety Issue: | |
Description: | To evaluate PK parameter - AUC0-last (Area under the concentration-time curve (AUC) from time zero to last quantifiable sample) |
Measure: | Pharmacokinetics concentration of epcoritamab |
Time Frame: | From start of treatment throughout all treatment cycles (each cycle is 28 days) until LPLV, approximately 3 years |
Safety Issue: | |
Description: | To evaluate PK parameter - Area under the concentration-time curve (AUC) from time zero to infinity |
Measure: | Pharmacokinetics concentration of epcoritamab |
Time Frame: | From start of treatment throughout all treatment cycles (each cycle is 28 days) until LPLV, approximately 3 years |
Safety Issue: | |
Description: | To evaluate PK parameter - Cmax (maximum (peak) plasma drug concentration) |
Measure: | Pharmacokinetics concentration of epcoritamab |
Time Frame: | From start of treatment throughout all treatment cycles (each cycle is 28 days) until LPLV, approximately 3 years |
Safety Issue: | |
Description: | To evaluatePK parameter - Tmax (time to reach maximum (peak) plasma concentration) |
Measure: | Pharmacokinetics concentration of epcoritamab |
Time Frame: | From start of treatment throughout all treatment cycles (each cycle is 28 days) until LPLV, approximately 3 years |
Safety Issue: | |
Description: | To evaluate PK parameters - Predose values |
Measure: | Pharmacokinetics concentration of epcoritamab |
Time Frame: | From start of treatment throughout all treatment cycles (each cycle is 28 days) until LPLV, approximately 3 years |
Safety Issue: | |
Description: | To evaluate PK parameters - t½ (elimination half-life) |
Measure: | Incidence of anti-drug antibodies (ADAs) to Epcoritamab |
Time Frame: | From start of treatment until end of treatment, approximately 24 months |
Safety Issue: | |
Description: | To evaluate immunogenicity |
Measure: | Duration of response (DOR) |
Time Frame: | Approximately 3 years after the last subject's first treatment |
Safety Issue: | |
Description: | To evaluate the preliminary anti-tumor activity of epcoritamab in combination with other agents |
Measure: | Time to response (TTR) |
Time Frame: | Approximately 3 years after the last subject's first treatment |
Safety Issue: | |
Description: | To evaluate the preliminary anti-tumor activity of epcoritamab in combination with other agents |
Measure: | Progressive-free survival (PFS) |
Time Frame: | Approximately 3 years after the last subject's first treatment |
Safety Issue: | |
Description: | To evaluate the preliminary anti-tumor activity of epcoritamab in combination with other agents |
Measure: | Overall survival (OS) |
Time Frame: | Approximately 3 years after the last subject's first treatment |
Safety Issue: | |
Description: | To evaluate the preliminary anti-tumor activity of epcoritamab in combination with other agents |
Measure: | Time to next anti-lymphoma therapy (TTNT) |
Time Frame: | Approximately 3 years after the last subject's first treatment |
Safety Issue: | |
Description: | To evaluate the preliminary anti-tumor activity of epcoritamab in combination with other agents |
Measure: | Rate of minimal residual disease (MRD) negativity |
Time Frame: | Approximately 3 years after the last subject's first treatment |
Safety Issue: | |
Description: | To evaluate the preliminary anti-tumor activity of epcoritamab in combination with other agents |
Measure: | Duration of minimal residual disease (MRD) negativity |
Time Frame: | Approximately 3 years after the last subject's first treatment |
Safety Issue: | |
Description: | To evaluate the preliminary anti-tumor activity of epcoritamab in combination with other agents |
Measure: | Safety run-in only: preliminary anti-tumor activity as measured by the overall response rate |
Time Frame: | Approximately 3 years after the last subject's first treatment |
Safety Issue: | |
Description: | To evaluate the preliminary anti-tumor activity of epcoritamab in combination with other agents |
Measure: | Expansion only: Monitor number and severity of AEs |
Time Frame: | Up to safety follow-up (up to 60days after last dose) |
Safety Issue: | |
Description: | To evaluate the safety and tolerability of epcoritamab in combination with other agents |
Measure: | Expansion only: Monitor number and severity of changes in laboratory values |
Time Frame: | Up to safety follow-up (up to 60days after last dose) |
Safety Issue: | |
Description: | To evaluate the safety and tolerability of epcoritamab in combination with other agents |
Measure: | Expansion only: Monitor number of dose interruptions and delays |
Time Frame: | Up to safety follow-up (up to 60days after last dose) |
Safety Issue: | |
Description: | To evaluate the safety and tolerability of epcoritamab in combination with other agents |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Genmab |
Last Updated
June 15, 2021